Sysmex Corporation
Sysmex Corporation is a Japanese in vitro diagnostics company that develops and sells automated hematology, hemostasis, urinalysis, and flow cytometry analyzers, along with reagents and informatics, serving 12,000+ clinical laboratories worldwide and performing over 400 million CBCs annually.
- Company typePublic
- Founded1968
- HeadquartersHyogo, Japan
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Sysmex Corporation does
Sysmex Corporation is a Japanese in vitro diagnostics company founded in 1968 and headquartered in Kobe, Japan, publicly listed in Tokyo and on OTCMKTS (SSMXY), with global operations including an Americas regional affiliate (Sysmex America, Inc.) in Lincolnshire, Illinois, and a Canadian subsidiary. The company specializes in clinical laboratory diagnostics spanning five solution areas: Hematology (XN-Series and the new XR-Series automated analyzers), Hemostasis (CN-Series and CS-Series coagulation analyzers), Urinalysis (UN-Series integrating UF-5000 particle counting with Siemens CLINITEK Novus chemistry and UD-10 digital imaging), Flow Cytometry, and Informatics Solutions (Caresphere Workflow Solution, BeyondCare Quality Monitor, and the Sysmex Network Communications System). The core technical platform is fluorescent flow cytometry using semiconductor laser and hydrodynamic focusing, complemented by AI-based digital cell morphology on the DI-60 system via artificial neural network pre-classification, and a proprietary informatics stack that integrates analyzers with peer QC and workflow automation.
Sysmex's business model combines hardware sales of analyzers with high-margin recurring revenue from proprietary reagents and consumables, plus multi-year service and support contracts delivered through programs like BeyondCare and SNCS remote monitoring. The company sells primarily through direct enterprise field sales to hospitals, reference laboratories, and clinical labs across the Americas, complemented by regional distributors in Latin America, Central America, Mexico, and the Caribbean, with self-described reach across 20+ countries. Pricing is quote-based on multi-year contracts structured around lab size and testing volume; no public list pricing is disclosed. The installed base comprises 12,000+ clinical laboratories worldwide performing 400+ million CBCs annually, producing deeply embedded switching costs through reagent attachment, IT integrations (Bio-Rad Unity Next, CellaVision software stack), and validated clinical workflows.
Recent strategic activity shows Sysmex leveraging this installed base and regulated distribution muscle to extend into adjacent verticals: regenerative medicine via the 2023 acquisition of iPS cell company Megakaryon; Alzheimer's/dementia immunoassays via the 2026 Fujirebio sales collaboration; AI-based bone marrow analysis via the 2026 CellaVision EMEA distribution partnership; and sepsis/NETs diagnostics via the 2026 VolitionRx collaboration. Product refreshes include the XR-Series hematology launch (2026-05) and the announced CN-9000 hemostasis system (2026-07), alongside a 2023 European first for point-of-care antimicrobial susceptibility testing. The portfolio continues to be anchored by core XN-Series hematology analyzers, hemostasis platforms with Preanalytical Sample Integrity (PSI) checks, and integrated urinalysis solutions, with the 26-consecutive-year #1 IMV ServiceTrak system reliability ranking reinforcing the company's brand moat in regulated clinical environments.
Sysmex Corporation firmographics
Firmographics- Name
- Sysmex Corporation
- Legal name
- Sysmex America, Inc.
- Website
- https://sysmex.com
- Company type
- Public
- Founded year
- 1968
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Sysmex Corporation is a Japanese in vitro diagnostics company that develops and sells automated hematology, hemostasis, urinalysis, and flow cytometry analyzers, along with reagents and informatics, serving 12,000+ clinical laboratories worldwide and performing over 400 million CBCs annually.
- Ownership category
- akta.pro rank
Sysmex Corporation industry classification
Industry- Product category
- Clinical Diagnostics Instruments
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL)
- akta.pro secondary industries
- IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM), Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing) (HLAAALAH)
Keywords
Where Sysmex Corporation is headquartered
LocationHeadquarters
- HQ city
- Hyogo
- HQ country
- Japan
- HQ region
- Asia
Offices3 records
Markets served
Sysmex Corporation business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Hematology Instruments and Reagents: Sale and servicing of automated hematology analyzers (XN-Series, XR-Series) along with配套 reagents and consumables for complete blood count testing
- Urinalysis Systems: Integrated urinalysis solutions combining particle counting, chemistry analysis, and digital imaging with配套 reagents
- Hemostasis/Coagulation Products: Blood coagulation analyzers (CN-6000, CS-5100, CS-2500, CA-600) and reagents for hemostasis testing including clotting, chromogenic, and immunoturbidimetric assays
- Flow Cytometry Instruments and Reagents: Clinical flow cytometry systems and reagents for immunophenotyping and cell analysis applications
- Service and Support Contracts: Technical support, maintenance, calibration, and remote monitoring services through Sysmex Network Communications System (SNCS) and BeyondCare programs
- Digital PCR and Molecular Diagnostics: Advanced molecular diagnostic technologies including digital PCR capabilities and integrated diagnostic solutions for precision medicine applications
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Enterprise laboratory instrumentation and reagents |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels7 records
Sysmex Corporation product offering
Product offeringCore offering
Sysmex Corporation manufactures and globally distributes in vitro diagnostic analyzers, proprietary reagents, and laboratory informatics software for clinical laboratories. Its core product lines span hematology, hemostasis/coagulation, urinalysis, flow cytometry, and immunochemistry analyzers, paired with corresponding reagents and consumables used by hospital labs, reference labs, and blood centers.
Product overview
Sysmex Corporation offers a comprehensive diagnostic solutions portfolio organized into five core areas: Hematology, Hemostasis, Urinalysis, Flow Cytometry, and Informatics Solutions. The hematology portfolio includes the XN-Series automated analyzers (XN-1000, XN-2000, XN-3100, XN-9100) using fluorescent flow cytometry technology, complemented by the new XR-Series generation launched in 2026. Supporting products include SP-50 slidemaker/stainer, DI-60 digital cell morphology system with AI-powered pre-classification, BT-50 automated QC terminal, TS-01 tube sorter, and TA-01 tube archiver. The hemostasis line features CN-6000 and CN-3000 high-throughput coagulation analyzers, CS-5100 and CS-2500 systems, and CA-600 Series for lower-volume labs, all incorporating Preanalytical Sample Integrity (PSI) technology. Urinalysis solutions comprise the UN-Series (UN-2000, UN-3000, UN-9000) integrating UF-5000 particle counting, Siemens CLINITEK Novus chemistry, and UD-10 digital imaging, managed through Urinalysis Data Manager (UDM). Informatics offerings include BeyondCare Quality Monitor (BCQM), Caresphere Workflow Solution (WS), and Sysmex Network Communications System (SNCS) for remote monitoring. The portfolio operates on a platform-plus-modules architecture with scalable automation options designed for laboratories of all sizes.
Differentiator
Problem solved
Functional benefit
Brands
- BeyondCare: Service and support program offering evidence-based maintenance, quality monitoring, and remote technical assistance for Sysmex analyzers.
- Caresphere
- Sysmex University
Products and services
- XN-Series Hematology Analyzers
Companies that use Sysmex Corporation
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles1 record
Sysmex Corporation technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration8 records
AI capability2 records
Feature7 records
Sysmex Corporation partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and strategic.
- VolitionRx LimitedcoreCollaboration to optimize VolitionRx's Nu.Q NETs H3.1 assay on Sysmex's in vitro diagnostics platform for detecting Neutrophil Extracellular Traps (NETs) associated with sepsis and other acute/chronic conditions. Companies have completed assay transfer and entered optimization phase. VolitionRx estimates $3.8 billion total addressable market for the Nu.Q NETs assay. Financial terms not disclosed.
- CellaVision ABcoreSysmex Corporation serves as exclusive distribution partner for CellaVision's AI-powered Bone Marrow Aspirate Application in EMEA region. Product runs on CellaVision DC-1 analyzer, automatically locates analysis areas, captures high-resolution images, and pre-classifies nucleated cells into 17 cell types. CE marked as Class C device under EU IVDR.
- Fujirebio HoldingscoreSales collaboration agreement for dementia testing where Sysmex exclusively sells Fujirebio's fully automated Lumipulse immunoassay systems and dementia-related reagents in regions mutually agreed upon. Collaboration begins in Brazil and progressively expands into Central and South America, Middle East, Asia, and other regions. Addresses growing demand for dementia testing accompanying adoption of new therapeutic drugs for Alzheimer's disease.
- Megakaryon CorporationstrategicSysmex acquired iPS (induced pluripotent stem cell) company Megakaryon to accelerate development of regenerative medicine. Acquisition strengthens Sysmex's position in cell therapy and regenerative medicine applications.
Scale indicators6 records
Recent moves6 records
Expansion highlights8 records
Sysmex Corporation competitors and assessment
Company assessmentDirect peers
- Beckman Coulter: Now part of Danaher's Diagnostics platform, Beckman Coulter is the closest direct competitor to Sysmex in hematology analyzers (DxH series) and offers overlapping urinalysis and hemostasis workflows for clinical laboratories.
- Bou Diagnostics (Boulex): Specialist hematology analyzer vendor (Medonic, Swelab) for low- and mid-volume labs; competes with Sysmex's XN-L and 3-part analyzer family in smaller hospital and clinic settings.
- Bio-Rad Laboratories: Provider of hematology controls (Liquichek) and Unity QC peer-comparison software; integrates with Sysmex XN-Series for QC management, making it both a partner and a complementary competitor for lab quality programs.
- Mindray: Chinese IVD player offering BC-7500/BC-6800Plus hematology analyzers and broader IVD menu; targets similar mid-to-high volume clinical lab segment and is an emerging direct global competitor to Sysmex, especially in emerging markets.
- Horiba Medical: Specialist hematology and hemostasis analyzer manufacturer (Pentra, Yumizen, ABX product lines) competing directly with Sysmex in small-to-mid volume hospital and physician-office lab segments.
Broad incumbents
- Siemens Healthineers: Diversified diagnostics incumbent offering Atellica/ADVIA Centaur hematology, hemostasis (BCS/XP), and integrated lab automation; Sysmex integrates with Siemens CLINITEK Novus urine chemistry within its UN-Series, making Siemens both a partner and competitor.
- Roche Diagnostics: Largest diagnostics incumbent globally with cobas hematology, coagulation, and integrated lab automation; competes for the same multi-year enterprise contracts and reference lab business as Sysmex.
- Abbott Diagnostics: Major IVD incumbent with CELL-DYN/Alinity hq hematology, broader immunoassay, and a leading point-of-care franchise (i-STAT); competes with Sysmex in hospital and reference lab channels across the full diagnostic menu.
Emerging players
- EKF Diagnostics: Smaller IVD player active in hematology (QuikRead, Hemo Control), point-of-care, and clinical chemistry; overlaps with Sysmex's lower-volume and decentralized testing footprint.
- CellaVision: Digital cell morphology specialist whose DC-1 analyzer and AI applications are distributed exclusively by Sysmex in EMEA; a channel partner that is also an emerging competitive threat in digital morphology as labs consider standalone digital solutions.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Sysmex Corporation social profiles
Digital presenceSysmex Corporation compliance and trust
Trust signalCompliance2 records
Sysmex Corporation financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sysmex Corporation leadership team
Management profileNumber of profiles
Profiles2 records
Sysmex Corporation subsidiaries and ownership
Company hierarchySubsidiaries2 records
Sysmex Corporation funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sysmex Corporation M&A and investment
M&A and investmentM&A2 records
Investments8 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sysmex Corporation
What does Sysmex Corporation do?
Sysmex Corporation manufactures and globally distributes in vitro diagnostic analyzers, proprietary reagents, and laboratory informatics software for clinical laboratories. Its core product lines span hematology, hemostasis/coagulation, urinalysis, flow cytometry, and immunochemistry analyzers, paired with corresponding reagents and consumables used by hospital labs, reference labs, and blood centers.
Is Sysmex Corporation a public or private company?
Sysmex Corporation is a public company. It is classified as public and is currently operating.
When was Sysmex Corporation founded?
Sysmex Corporation was founded in 1968. It employs 5,001 to 10,000 people.
Where is Sysmex Corporation based?
Sysmex Corporation is headquartered in Hyogo, Japan, in the Asia region.
How does Sysmex Corporation make money?
Six revenue lines are on record. Hematology Instruments and Reagents are the primary driver. The others are urinalysis Systems, hemostasis/Coagulation Products, flow Cytometry Instruments and Reagents, service and Support Contracts and digital PCR and Molecular Diagnostics.
Who are Sysmex Corporation's main competitors?
Direct peers on record are Beckman Coulter, Bou Diagnostics (Boulex), Bio-Rad Laboratories, Mindray and Horiba Medical. Broad incumbents are Siemens Healthineers, Roche Diagnostics and Abbott Diagnostics. Emerging players are EKF Diagnostics and CellaVision.
Does Sysmex Corporation have an API?
No public API is recorded for Sysmex Corporation.
What industry is Sysmex Corporation in?
Sysmex Corporation's product category is Clinical Diagnostics Instruments. Its primary akta.pro industry code is HLAAAMAL, Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls), with a secondary code of HLAHAAAM, IVD Reagents, Assay Kits & Consumables (Non-instrument). Its NAICS code is 325413 and its SIC code is 2835.